Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF(PILL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$13.08
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PILL

11/20/2026: PILL (1-star) is currently NOT-A-BUY. Pass it for now.

ETF PILL provides 3x daily leveraged exposure to an equal-weighted index of U.S. pharmaceutical companies primarily via swap agreements and derivatives. Its main strength lies in offering targeted high-beta exposure for tactical swing traders without requiring margin accounts. The fund functions strictly as a short-term trading vehicle rather than a long-term investment option. Its primary risks stem from daily compounding decay, high volatility, and concentration within the pharmaceutical industry. It suits experienced short-term momentum traders who actively monitor sector catalysts and exit positions rapidly.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitLong-term growth strategies clash with the daily-reset mechanics and decay risk of leveraged products.
Momentum investorStrong fit while signal remains positiveActive momentum traders can exploit short-term bullish trends in the pharmaceutical sector using triple daily leverage.
Value investorWeak fitThe fund's tactical derivative structure is unsuited for traditional fundamental valuation investing.
Dividend/Income investorWeak fitThe ETF distributes negligible dividend income and focuses strictly on capital movement.
Low-risk investorWeak fitExtreme volatility and daily compounding risk make this fund unsuitable for risk-averse portfolios.

Investor Profile

Ideal Investor Profile

Active tactical traders, day traders, and sophisticated market participants seeking short-term leveraged exposure to pharmaceutical catalysts.

Suitability

Best suited exclusively for short-term, intraday, or swing trading strategies, and strongly inappropriate for buy-and-hold or long-term investors.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighAmplified 3x daily swings expose investors to rapid, severe capital losses.
Market riskHighVulnerable to sudden regulatory, legal, or clinical setbacks in the pharmaceutical sector.
ConcentrationHighFocused entirely on U.S. pharmaceutical companies, limiting diversification.
Tracking/expenseMedium / highCompounding effects and a 0.98% expense ratio cause long-term returns to deviate from 3x index performance.
LiquidityMediumModerate trading volumes can impact execution costs during stressful market events.
Business/sector qualityMediumWhile underlying pharma firms are often stable cash-generators, the wrapper itself is a speculative instrument.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

PILL exhibits exceptionally high historical volatility due to its 3x daily leverage objective applied to a cyclical and news-driven sector.

Market Risk

Subject to intense sector-specific risks, including drug pipeline failures, regulatory scrutiny, patent expirations, and political pricing pressures.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
DerivativesS&P Pharmaceuticals Select Industry Index — seeks 3x daily return85Provides the primary financial derivatives and swap exposure required to deliver triple daily index performance.
SectorU.S. Pharmaceutical Equities Basket14Holds underlying physical stocks from the index to support derivative tracking and fund liquidity.
Cash/collateralCash and U.S. Treasury Securities1Maintains a minor collateral buffer to support daily margin and operational requirements.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type ETF
Historic Profit 108.7%
Avg. Invested days 45
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
ETF Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.